The future of organ and tissue transplantation: Can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection?

JAMA

Volumn 282, Issue 11, 1999, Pages 1076-1082

  Harlan, David M ^b   Kirk, Allan D ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TISSUE TRANSPLANTATION;

EID: 0033568118     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.11.1076     Document Type: Review

References (68)

1. United Network for Organ Sharing Web site. Available at: http://www.unos.org. Accessed August 20, 1999.
2. National Center for Health Statistics. Advance Report of Final Mortality Statistics, 1986. Hyattsville, Md: US Dept of Health and Human Services, Public Health Service, Centers for Disease Control; 1988. DHHS publication (PHS) 88-112037, supplement.
3. Nagano H, Tilney NL. Chronic allograft failure: the clinical problem. Am J Med Sci. 1997;313:305-309.
4. Cecka JM. The UNOS scientific renal transplant registry: ten years of kidney transplants. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1997. Los Angeles, Calif: UCLA Tissue Typing Laboratory; 1998; 1-15.
5. Monaco AP, Burke JF Jr, Ferguson RM, et al. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion [review]. Am J Kidney Dis. 1999; 33:150-160.
6. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence [review]. J Am Soc Nephrol. 1999;10:167-181.
7. Hayry P. Chronic allograft vasculopathy: new strategies for drug development [review]. Transplant Proc. 1998;30:3989-3990.
8. Kendall DM, Robertson RP. Pancreas and islet transplantation: challenges for the twenty-first century [review]. Endocrinol Metab Clin North Am. 1997;26: 611-630.
9. Tibell A, Brendel M, Wadstrom J, et al. Early experience with a long-distance collaborative human islet transplant programme. Transplant Proc. 1997;29: 3124-3125.
10. Alejandro R, Lehmann R, Ricordi C, et al. Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes. 1997;46:1983-1989.
11. Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology. 1997; 113:1767-1778.
12. Hilbrands LB, Hoitsma AJ, Koene KA. Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Transplantation. 1996;61:1038-1046.
13. Becker BN, Stone WJ. Options for renal replacement therapy: special considerations. Semin Nephrol. 1997;17:176-187.
14. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997;10:136-145.
15. Buckels JA. Liver transplantation: current status, complications and prevention. J Antimicrob Chemother. 1995;36(suppl B):39-49.
16. Chaparro C, Kesten S. Infections in lung transplant recipients. Clin Chest Med. 1997;18:339-351.
17. DeChristopher PJ, Anderson RR. Risks of transfusion and organ and tissue transplantation: practical concerns that drive practical policies [review]. Am J Clin Pathol. 1997;107(4 suppl 1):S2-S11.
18. Mutimer D. CMV infection of transplant recipients [review]. J Hepatol. 1996;25:259-269.
19. Burnet FM. "Self-recognition" in colonial marine forms and flowering plants in relation to the evolution of immunity. Nature. 1971;232:230-235.
20. Scofield VL, Schlumpberger JM, West LA, Weissman IL. Protochordate allorecognition is controlled by a MHC-like gene system. Nature. 1982;295:499-502.
21. Vogel G. Fly development genes lead to immune find [published correction appears in Science. 1998;282:417]. Science. 1998;281:1942-1944.
22. Sprent J, Tough DF, Sun S. Factors controlling the turnover of T memory cells [review]. Immunol Rev. 1997;156:79-85.
23. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 1975; 53:27-42.
24. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science. 1970;169:1042-1049.
25. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later [review]. Immunol Today. 1992;13:74-76.
26. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol. 1987;7:4472-4481.
27. Ledbetter JA, Parsons M, Martin PJ, Hansen JA, Rabinovitch PS, June CH. Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol. 1986;137:3299-3305.
28. Freedman AS, Freeman G, Horowitz JC, Daley J, Nadler LM. B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol. 1987;139:3260-3267.
29. Freeman GJ, Gray GS, Gimmi CD, et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med. 1991;174:625-631.
30. Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993;262: 909-911.
31. Borriello F, Sethna MP, Boyd SD, et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin dass switching and germinal center formation. Immunity. 1997;6:303-313.
32. Harper K, Balzano C, Rouvier E, Mattëi MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol. 1991; 147:1037-1044.
33. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991; 174:561-569.
34. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541-547.
35. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995;270:985-988.
36. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 1992;257:792-795.
37. Korthauer U, Graf D, Mages HW, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 1993; 361:539-541.
38. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science. 1992;257:789-792.
39. Lenschow DJ, Zeng Y, Hathcock KS, et al. Inhibition of transplant rejection following treatment with anti B7-2 and anti-B7-1 antibodies. Transplantation. 1995;60:1171-1178.
40. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med. 1993;178: 1801-1806.
41. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A. 1992; 89:11102-11105.
42. Zheng XX, Sayegh MH, Zheng XG, et al. The role of donor and recipient B7-1 (CD80) in allograft rejection. J Immunol. 1997;159:1169-1173.
43. Chandraker A, Azuma H, Nadeau K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest. 1998;101:2309-2318.
44. Glysing-Jensen T, Raisanen-Sokolowski A, Sayegh MH, Russell ME. Chronic blockade of CD28-B7-mediated T-cell costimulation by CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts. Transplantation. 1997;64: 1641-1645.
45. Azuma H, Chandraker A, Nadeau K, et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A. 1996;93:12439-12444.
46. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac rejection in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest. 1996;97:833-838.
47. Parker DC, Greiner DL, Phillips NE, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A. 1995;92: 9560-9564.
48. Rossini AA, Parker DC, Phillips NE, et al. Induction of immunological tolerance to islet allografts. Cell Transplant. 1996;5:49-52.
49. + T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 1997;158:29-39.
50. Lu L, Li W, Fu F, et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived denritic cell progenitors to induce long-term cardiac allograft survival. Transplantation. 1997; 64:1808-1815.
51. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection: suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation. 1996;61:4-9.
52. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascuiarized murine cardiac allograft rejection. Proc Natl Acad Sci U S A. 1996;93:13967-13972.
53. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance [review]. Curr Opin Immunol. 1997;9:641-647.
54. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997;94:8789-8794.
55. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4-Ig in a nonhuman primate model of allogeneic pancreatic islet transplantation. J Immunol. 1997;159:5187-5191.
56. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996; 381:434-438.
57. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999;5:686-693.
58. Kenyon NS, Chatzipetrou M, Masetti M, et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A. 1999;96:8132-8137.
59. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection [review]. W Engl J Med. 1998;338:1813-1821.
60. Harlan DM, Kirk AD. Anti-CD154 and the prevention of graft rejection. Graft. 1998;1:60-70.
61. + T-helper and a T-killer cell. Nature. 1998;393:474-478.
62. Schoenberger SP, Toes RE, van der Voort El, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
63. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998; 393:478-480.
64. Lanzavecchia A. Immunology: license to kill. Nature. 1998;393:413-414.
65. Early CS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black × New Zealand white mice: response correlates with the absence of an anti-antibody response. J Immunol. 1996; 157:3159-3164.
66. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol. 1995; 154:1470-1480.
67. Fishman JA, Rubin RH. Infection in organtransplant recipients [review]. N Engl J Med. 1998; 338:1741-1751.
68. Pirsch JD. Long-term management of the immunosuppression in the renal transplant patient. Curr Opin Organ Transplantation. 1997;2:76-81.